Commerzbank Aktiengesellschaft FI bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 4,656 shares of the biopharmaceutical company’s stock, valued at approximately $378,000. Several other institutional investors and hedge funds have […]
Signaturefd LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 10.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,992 shares of the biopharmaceutical company’s stock after purchasing an additional 2,249 shares during the quarter. Signaturefd LLC’s holdings in Gilead […]
Gilead Sciences (NASDAQ:GILD – Get Free Report)‘s stock had its “outperform” rating reissued by equities research analysts at Oppenheimer in a research note issued to investors on Friday, Benzinga reports. They currently have a $105.00 price objective on the biopharmaceutical company’s stock. Oppenheimer’s price target suggests a potential upside of 58.04% from the company’s current […]
Eukles Asset Management lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 3.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,218 shares of the biopharmaceutical company’s stock after selling 469 shares during the period. Eukles Asset Management’s holdings […]
Flputnam Investment Management Co. increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 15.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,070 shares of the biopharmaceutical company’s stock after acquiring an additional 826 […]